Research programme: protein tyrosine kinase inhibitors - ARIADAlternative Names: AP 23864; AP 23994; AP 24163; Inhibitor A; Oncogenic kinase inhibitors - ARIAD
Latest Information Update: 17 Feb 2017
At a glance
- Originator ARIAD Pharmaceuticals
- Class Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Solid tumours